LiDCO has delivered FY20 results in line with expectations, with the key metric of own product sales coming in at +19%, a strong performance especially in light of the ongoing transition to the HUP SaaS model. Post period-end, LiDCO has experienced a surge in demand for its monitors, particularly as UK hospitals scramble to increase critical care capacity. As a result, LiDCO has sold 195 monitors YTD vs 219 in the whole of FY20. Whilst some of the associated revenue uplift is likely to be sho
21 Apr 2020
In line FY20, exceptionally strong Q1
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line FY20, exceptionally strong Q1
- Published:
21 Apr 2020 -
Author:
Chris Glasper -
Pages:
3
LiDCO has delivered FY20 results in line with expectations, with the key metric of own product sales coming in at +19%, a strong performance especially in light of the ongoing transition to the HUP SaaS model. Post period-end, LiDCO has experienced a surge in demand for its monitors, particularly as UK hospitals scramble to increase critical care capacity. As a result, LiDCO has sold 195 monitors YTD vs 219 in the whole of FY20. Whilst some of the associated revenue uplift is likely to be sho